CK Life Sciences Intl : Termination of Discloseable Transaction in respect of the Acquisition of Nangiloc Colignan Farms

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 0775)

TERMINATION OF DISCLOSEABLE TRANSACTION

IN RESPECT OF

THE ACQUISITION OF NANGILOC COLIGNAN FARMS

Reference is made to the announcement of CK Life Sciences Int'l., (Holdings) Inc., dated 9 March 2018 (the "Announcement"), in respect of the discloseable transaction in relation to, among other things, the Acquisition as contemplated under the Property Contract and the NSW WAL Contract. Unless the context otherwise requires, capitalised terms used herein shall have the same meanings as those defined in the Announcement.

As disclosed in the Announcement, Settlement is conditional upon the satisfaction of conditions precedent as referred to in the Announcement, and the Property Contract and the NSW WAL Contract must be settled simultaneously with the settlement of each of the Transaction Documents, namely, the Property Contract, the NSW WAL Contract and the Business Sale and Purchase Agreement. The original Sunset Date (i.e. 30 April 2018) for satisfaction of the conditions precedent for the Acquisition and for interdependent settlement of the Transaction Documents was extended to 31 May 2018.

The Purchaser was informed by the Vendors on 1 June 2018 that the Business Sale and Purchase Agreement entered between the Business Sellers and Business Buyers, being one of the Transaction Documents, was terminated on 31 May 2018 as certain conditions precedent had not been satisfied. The Business Buyers and the Purchaser then continued to engage in discussions with the Vendors, in an effort to determine whether, despite the termination, the transactions contemplated under the Transaction Documents could nonetheless proceed.

Despite their efforts, no further agreement has been reached between the parties and pursuant to the Umbrella Deed, the Property Contract and the NSW WAL Contract were also deemed to be terminated with effect from 31 May 2018 and the parties to the Acquisition were released from their respective obligations thereunder. The Acquisition under the Property Contract and the NSW WAL Contract will therefore not proceed further. The Purchaser is reviewing its options and, if applicable, further announcement will be made in due course.

By Order of the Board

CK Life Sciences Int'l., (Holdings) Inc.

Eirene Yeung

Company Secretary

Hong Kong, 11 June 2018 -1 -

As at the date of this announcement, the Executive Directors of the Company are Mr. Li Tzar Kuoi, Victor (Chairman), Mr. Kam Hing Lam, Mr. Ip Tak Chuen, Edmond, Mr. Yu Ying Choi, Alan Abel and Dr. Chu Kee Hung; and the Non-executive Directors are Mr. Peter Peace Tulloch, Mrs. Kwok Eva Lee (Independent Non-executive Director), Mr. Colin Stevens Russel (Independent Non-executive Director) and Mr. Kwan Kai Cheong (Independent Non-executive Director).

-2 -